Dr. Michael Gold, MD
Claim this profileOklahoma Cancer Specialists and Research Institute
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
19 reported clinical trials
33 drugs studied
About Michael Gold, MD
Education:
- Obtained MD from the University of Oklahoma College of Medicine in 1987.
- Completed Residency in Internal Medicine at the University of Oklahoma Health Sciences Center in 1990.
- Finished Fellowship in Hematology/Oncology at the same institution in 1992.
Experience:
- Affiliated with Oklahoma Cancer Specialists and Research Institute.
- Specializes in medical oncology and hematology.
Area of expertise
1Ovarian Cancer
Stage IV
Stage III
FRα positive
2Fallopian Tube Cancer
Stage III
Stage IV
FRα positive
Affiliated Hospitals
Clinical Trials Michael Gold, MD is currently running
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
Selinexor Maintenance Therapy
for Endometrial Cancer
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Recruiting1 award Phase 32 criteria
More about Michael Gold, MD
Clinical Trial Related5 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Michael Gold, MD has experience with
- Paclitaxel
- Placebo
- Carboplatin
- Mirvetuximab Soravtansine
- Juvéderm® Voluma™ XC
- Saypha® VOLUME Lidocaine
Breakdown of trials Michael Gold, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasm
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Gold, MD specialize in?
Michael Gold, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Michael Gold, MD currently recruiting for clinical trials?
Yes, Michael Gold, MD is currently recruiting for 4 clinical trials in Tulsa Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Michael Gold, MD has studied deeply?
Yes, Michael Gold, MD has studied treatments such as Paclitaxel, Placebo, Carboplatin.
What is the best way to schedule an appointment with Michael Gold, MD?
Apply for one of the trials that Michael Gold, MD is conducting.
What is the office address of Michael Gold, MD?
The office of Michael Gold, MD is located at: Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma 74146 United States. This is the address for their practice at the Oklahoma Cancer Specialists and Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.